85-1562-91　Protein Kinase Inhibitor (PKI, SP600125Anthra[1,9-cd]pyrazol-6(2H)-one) 300mg　CAS No:129-56-6　P9104-77A

特徴

• Novel, potent and selective JNK-1,-2, and -3 inhibitor (Ki=0.19uM). SP600125 is an ATP-competitive reversible inhibitor with >20-fold selectivity vs. a range of kinases and enzymes tested. In cells, SP600125 caused a dose-dependent inhibition of the phosphorylation of c-Jun, the expression of inflammatory genes IL-2, COX-2, TNF-a, IFN-gamma, and blocked the activation and differentiation of primary human CD4 cell cultures. In animal studies, SP600125 inhibited bacterial lipopolysaccharide-induced expression of tumor necrosis factor-a and prevented anti-CD3-induced apoptosis of CD4+ CD8+ thymocytes.
• Melting Point:As reported
• Solubility:Prepare initial stock solutions in DMSO (soluble at 65mg/ml) for in vitro use; solubility in ethanol or water is low.
• Storage and Stability:May be stored at RT for short-term only. Long-term storage is recommended at -20°C under inert atmosphere. For maximum recovery of product, centrifuge the original vial prior to removing the cap.

仕様

• Size：300mg
• Grade：Highly Purified
• Purity：~99%
• Form：Supplied as a yellow to green powder.
• Molecular Formula：C14H8N2O
• Molecular Weight Non Ab：220.23
• EU Commodity Code：38220090
• この商品は法規制を確認しておりません。(法規制によって販売できない場合もございます)
• 製品の仕様は予告なく変更になる場合がございます。最新仕様はメーカーホームページをご確認ください。
• CAS No ：129-56-6

• 【試薬に関するお問合せ】
• アズワン株式会社 試薬・プロセス材料グループ
• TEL：06-6447-8641
• FAX：06-6447-8642
• E-mail：[email protected]